Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Total Non-Current Liabilities (2016 - 2025)

Alterity Therapeutics has reported Total Non-Current Liabilities over the past 5 years, most recently at $24499.7 for Q2 2019.

  • For Q2 2019, Total Non-Current Liabilities rose 3433.04% year-over-year to $24499.7; the TTM value through Jun 2019 reached $24499.7, up 3433.04%, while the annual FY2019 figure was $24499.7, 3433.04% up from the prior year.
  • Total Non-Current Liabilities for Q2 2019 was $24499.7 at Alterity Therapeutics, up from $0.93 in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $24499.7 in Q2 2019 and troughed at $0.3 in Q2 2017.
  • A 5-year average of $2942.1 and a median of $347.32 in 2016 define the central range for Total Non-Current Liabilities.
  • On a YoY basis, Total Non-Current Liabilities climbed as much as 230676.19% in 2018 and fell as far as 99.81% in 2018.
  • Year by year, Total Non-Current Liabilities stood at $454.12 in 2015, then dropped by 23.52% to $347.32 in 2016, then soared by 38.39% to $480.65 in 2017, then tumbled by 99.81% to $0.93 in 2018, then skyrocketed by 2626890.29% to $24499.7 in 2019.
  • Business Quant data shows Total Non-Current Liabilities for ATHE at $24499.7 in Q2 2019, $0.93 in Q4 2018, and $693.45 in Q2 2018.